Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2020 Jan 23;19(3):755–764. doi: 10.1158/1535-7163.MCT-19-0947

Figure 4: Pharmacological inhibition of Syk kinase inhibits tumor growth and promotes CD8+ T cell recruitment and activation.

Figure 4:

A. Tumor volume of LLC inoculated subcutaneously in WT mice treated with 40 mg/kg R788 (n=6). B. Relative mRNA expression of TAMs from LLC tumors grown in WT animals and treated with R788. **p<0.01 and *p<0.05, t test C. FACS quantification of percentage of CD4+ and CD8+ T cells (gated on CD3+ T cells) in R788 treated LLC tumors (n=3, p<.05, t test). D. Flow cytometric representation of CD4+FoxP3+ regulatory T cells in the LLC tumors treated with R788. E. FACS analysis of CD44+CD62L- effector T cells (gated on CD8+ T cells) in R788 treated tumors (n=3), ** p<0.05, t test. F. In vitro tumor cell cytotoxicity induced by T cells isolated from R788 treated tumors (n=3), *** p<0.001, 2-way ANOVA using Bonferroni test.